Background. Thrombelastography platelet mapping is a useful assay to assess antiplatelet therapy. Inhibited response to the adenosine diphosphate receptor on platelets occurs early after injury, but recent work suggests this alteration occurs even with minor trauma. However, the utility of thrombelastography platelet mapping, specifically the percent of adenosine diphosphate receptor inhibition, in predicting outcomes and guiding platelet transfusion in trauma-induced coagulopathy remains unknown We assessed the role of percent of adenosine diphosphate-inhibition in predicting survival, requirement for massive transfusion or platelet transfusion in patients at risk for trauma-induced coagulopathy. Methods. Thrombelastography platelet mapping was assessed in 303 trauma activation patients from 2014-2016 and in 89 healthy volunteers. Percent of adenosine diphosphate-inhibition is presented as median and interquartile range. We compared the area under the receiver operating characteristic curve of percent of adenosine diphosphate-inhibition, platelet count, and rapid thrombelastography maximum amplitude for in-hospital mortality, massive transfusion (>10 red blood cells or death/6 hours), and platelet transfusion (>0 platelet units or death/6 hour). Results. Overall, 35 (11.5%) patient died, 27 (8.9%) required massive transfusion and 46, platelet transfusions (15.2%). Median percent of adenosine diphosphate-inhibition was 42.5% (interquartile range: 22.4-69.1%), compared with 4.3 % (interquartile range: 0-13.5%) in healthy volunteers (P < .0001). Patients that died, had a massive transfusion, or platelet transfusion had higher percent of adenosine diphosphate-inhibition than those that did not (P < .05 for all). However, percent of adenosine diphosphate-inhibition did not add significantly to the predictive performance of maximum amplitude or platelet count for any of the 3 outcomes, after adjustment for confounders. Subgroup analyses by severe traumatic brain injury, severe injury and requirement of red blood cells showed similar results. Conclusion. Adenosine diphosphate receptor inhibition did not add predictive value to predicting mortality, massive transfusion, or platelet transfusion. Thus, the role of thrombelastography platelet mapping as a solitary tool to guide platelet transfusions in trauma requires continued refinement. (Surgery 2017;162:1286-94.) 
UNCONTROLLED HEMORRHAGE is the leading causes of preventable death from trauma and occurs predominantly within 2 hours of injury. 1 An endogenous trauma-induced coagulopathy (TIC) is the driving mechanism and, if present at admission, is associated with a 4-fold increase in mortality. 2 TIC is a multifocal process attributed to reduced thrombin generation, fibrinogen depletion, platelet dysfunction, and systemic fibrinolysis. [3] [4] [5] Consequently, early blood component administration is now standard in patients at risk for TIC. 5 However, the optimal composition of blood components remains debated. A large multicenter randomized controlled trial, Pragmatic Randomized Optimal Platelet and Plasma Ratios, indicated no survival benefit of empiric immediate platelet transfusion. 6 Our recent goal-directed resuscitation trial based on viscoelastic assays indicated a 50% reduction in mortality, but current thrombelastography (TEG) and thromboelastometry assays do not include a measurement specific for platelet transfusion. 7 Although these devices are capable of measuring platelet receptor inhibition to monitor antiplatelet therapy, 8 their role in guiding platelets transfusions for TIC remains unclear. The present TEG platelet mapping (TEG-PM) assays represent the responses to arachidonic acid (AA), which serves as substrate for cyclooxygenase dependent thromboxane A2 that binds to the thromboxane (TP) receptor, or adenosine diphosphate (ADP), which binds to platelet P2Y1 and P2Y12 receptors. 9 ADP is released from the dense granules of platelets. Simplistically, the inner core of a blood clot (primary hemostasis) is composed of activated platelets in an environment abundant in thrombin and fibrin; whereas, platelet released TXA2 and ADP are thought to be important in the formation of the subsequent outer core of less active platelets. 9, 10 Our previous work has shown that inhibited platelet response to AA after trauma is nonspecific. 3 Consequently, our group and others have focused on the ADP response in TEG-PM to determine its role in guiding platelet transfusion. 3, 11 Although inhibited platelet response to ADP after injury has been suggested to represent an exhausted platelet, recent work does not support this concept. 12 Specifically, trauma patients maintain their dense granules even in the presence of ADP receptor inhibition contradicting the theory of platelet granule exhaustion as the etiology for platelet dysfunction. 12 Furthermore, other studies have documented a significant inhibited response to ADP after minor trauma, suggesting receptor status may be a biomarker of injury rather than a mediator of TIC. 13 Therefore, we propose to assess the role of platelet ADP receptor dysfunction, measured by TEG-PM mapping in predicting mortality, requirement of massive transfusion and platelet transfusion among patients at risk for TIC.
METHODS
Study design. This is an analysis of prospectively collected data from our Trauma Activation Protocol from 2014 to 2016 database (TAP database), which includes patients who met criteria for the highest level of trauma team activation at Denver Health Medical Center, an American College of Surgeons verified and Colorado state certified Level 1 trauma center affiliated with the University of Colorado Denver. The Colorado Multiple Institutional Review Board approved all studies included in the TAP database. We did not exclude patients who were taking medications affecting coagulation or platelet function, as this information is rarely available or reliable upon admission.
Clinical data were collected by trained research professional assistants and included: age, sex, mechanism, body mass index, new injury severity score, field and hospital arrival systolic blood pressure, heart rate, Glasgow Coma Scale, international normalized ratio, partial thromboplastin time, fibrinogen, base deficit, as well as number of units of blood products transfused (red blood cells [RBCs] ), fresh frozen plasma [FFP] , platelets, cryoprecipitate) and volume of crystalloid infused. Severe traumatic brain injury (TBI) was defined as abbreviated injury scale [AIS]-head $3.
Outcome variables: The outcomes of this study were: 1) in-hospital death within 28 days postinjury; 2) massive transfusion, defined as >10 units of RBCs or death within 6 hours [3] [4] [5] [6] ; and 3) platelet transfusion: defined as platelet transfusion or death within 6 hours of injury. The death criterion was added to both massive transfusion and platelet transfusion to minimize survivor bias (ie, nonsurvivors did not have the "opportunity" to receive transfusions).
Main effect variables: the main effects in this study were: 1) % ADP INH; 2) platelet count; 3) rapid thrombelastography (rTEG) MA. All these variables were obtained within 1 hour after injury.
The protocol for massive transfusion of blood products has been described previously and includes initial empiric initial transfusion of FFP:RBC 1:2 14 followed by a standardized rTEG guided hemostatic resuscitation. 15 Transfusion was triggered if the patient was perceived to have ongoing blood loss and had the after TEG-derive parameters; FFP for activated clotting time (ACT) >128, cryoprecipitate for angle <65, platelets for maximum amplitude (MA) <55 and, tranexamic 
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Demographic characteristics of all patients and patients stratified by the 3 major outcomes (in-hospital death, massive transfusion, platelet transfusion). Data are presented as median with lower and upper quartile in parentheses or as percentage (%). *P < .01, yP < .05 comparing survivors with nonsurvivors. zP < .01 comparing massive Tx to no massive Tx. xP < .01, {P < .05 comparing platelet tx with no platelet tx. BMI, Body mass index; ED, emergency department; SBP, systolic blood pressure; HR, heart rate; GCS, Glasgow Coma Scale; INR, International Normalized Ratio; PTT, partial thromboplastin time; Tx, transfusion.
acid for lysis at 30 minutes after achieving MA (LY30) >5%, as described before. 15 PRBCs were transfused to maintain a hemoglobin at least 10 g/dL while bleeding was ongoing. Massive transfusion was stopped as clinically indicated, once control of bleeding was achieved and the patient was hemodynamically stable.
Blood samples from healthy volunteers. Trained study staff collected samples from volunteers at an outpatient clinic after obtaining an informed consent. The study was open to patients and hospital staff not taking antiplatelet or anticoagulant medications. Volunteers with diabetes, morbid obesity, renal disease, or liver disease were excluded. Blood samples were collected in tubes containing sodium citrate (3.5 mL, 3.2% sodium citrate, Greiner Bio-One, Monroe, North Carolina) or lithium heparin (4.0 mL, Greiner Bio-One).
Blood samples from trauma patients. Samples were collected during trauma activations in the field by trained paramedics or upon arrival to emergency department to evaluate the role of TEG in the management injury. Samples were collected in tubes containing sodium citrate and lithium heparin. A team of trained research professional assistants on 24/7 schedule for prospective studies completed viscoelastic assays within 2 hours after blood collection. Citrated blood samples were analyzed using the TEG 5000 Thrombelastography Hemostasis Analyzer (Haemonetics, Niles, IL). The following indices were obtained from the tracings of the TEG: ACT (sec), angle (8) ) was analyzed with the TEG platelet mapping assay (Haemonetics), and was mixed with a solution containing reptilase and FXIIIa to stimulate thrombin independent fibrin polymerization, and then activated with 2 MM ADP. The percent ADP receptor inhibition (% ADP-INH) was used to quantify platelet dysfunction.
Statistical analysis. Continuous variables were expressed as median and interquartile range (IQR) and the Wilcoxon nonparametric test was used for univariate comparisons. The v 2 and Fisher exact tests were used to compare categorical variables. Covariates with P value < .01 on univariate analysis and with minimal collinearity (Rho<j0.30j) were entered into logistic regression models for the defined outcomes and significant covariates were identified using stepwise selection. The performance of these models was assessed via measures of model discrimination (area under the receiver operating characteristic curves [AUROC] with 95% confidence intervals [95% CI]) and calibration (Hosmer-Lemeshow statistics, in which higher P values indicate better calibration). We then added the 3 effects of interest (%) to these models and compared the AUROC for the above described outcomes using the DeLong et al method. 16 We repeated these analyses in the subgroups with severe injuries (new injury severity score) AIS (abbreviated injury scale [NISS] $25), with TBI (AIS head/neck $3) and assessed the predictive performance of %ADP-INH and platelet count among patients with MA #55 mm. The optimal cutoffs for %ADP-INH, platelet count and TEG MA were estimated by the maximum value of the Youden Index (sensitivity + specificity À1) calculated using the ROC curves described above.
Sample size and power: assuming a 50% positive test (for %ADPINH, platelet count and rTEG MA), a moderate baseline AUROC of 0.72, and a higher than anticipated correlation of #0.60 between the effects of interest, a sample of 303 patients achieved 80% power to detect a difference of 0.09 in the AUROCs using a 2-sided at a significance level of 0.05 (PASS 14 Power Analysis and Sample Size software, 2015; NCSS, LLC, Kaysville, UT). All analyses were conducted using SAS 9.4 (SAS Institute Inc, Cary, NC). All tests were 2-tailed.
RESULTS
Patient characteristics. Of 436 consecutive trauma activation patients enrolled in our trauma activation database from 2014 to 2016, 303 (69.5%) had %ADP-INH measured within 1 hour of injury. Table I depicts the characteristics and injury severity for all patients and stratified by the 3 major outcomes (in-hospital death, massive transfusion, platelet transfusion). Overall, these were severely injured patients with a median NISS of 17 and base deficit-6 mEq/L. Mortality was 11.6%, massive transfusion was required in 8.9%, and platelet transfusion in 15.2%. Patients with these adverse outcomes had significantly higher %ADP-INH, lower platelet count, and lower rTEG MA, as well as worse levels of other indicators of injury severity (Table I ). Compared to healthy volunteers, injured patients had significantly higher %ADP-INH (Fig) . The median %ADP-INH was 42.5% (IQR: 22.4-69.1%) in trauma patients compared to 4.3% (IQR: 0-13.5%) in healthy volunteers.
Comparison between %ADP-INH, platelet count and rTEG-MA as predictors of death, massive transfusion and platelet transfusion, adjusted for significant covariates. Table II shows the significant covariates for the 3 selected outcomes. The models had excellent discrimination as indicated by the AUROCs and calibration (Hosmer-Lemeshow statistics with high P values). The 3 effects of interest were then added to these models initially one at a time (Table III) . Regarding death and massive transfusion, %ADP-INH, platelet count and MA did not add to the predictive performance of the predictors shown in Table II . However, both platelet count and MA significantly added to the other covariates in predicting the need for platelet transfusion, in contrast to %ADP-INH, which did not improve prediction.
When these 3 effects of interest were entered simultaneously into the models with the covariates shown in Table II , %ADP-INH did not show an independent association with any of the 3 outcomes. In contrast, low platelet count significantly predicted all 3 outcomes, and MA predicted massive transfusion (Table IV) . Table V shows a subgroup analysis of patients with NISS $25 (N = 124, 40.9%) and those with TBI (N = 80, 26.4%). In both subgroups, none of the 3 effects of interest were significantly superior than the model with the covariates in Table II Covariates with P value < .01 on univariate analysis and with minimal co-linearity (Rho<j0.30j) were entered into logistic regression models for the defined outcomes and significant covariates were identified using stepwise selection. The performance of these models was assessed via measures of model discrimination (AUROC curves) and calibration (Hosmer-Lemeshow statistics, in which higher P values indicate better calibration). TBI, NISS, and INR were the significant covariates identified for death while NISS, base deficit and partial thromboplastin time (PTT) were the covariates identified as the best predictors of massive transfusion and platelet transfusion. Once adjusted for significant covariates, %ADP-INH, platelet count and rTEG MAs performances were compared for 3 outcomes (death, massive transfusion, and platelet transfusion). Platelet count was a significant predictor of death and platelet transfusion while platelet count and rTEG MA were significant predictors of massive transfusion. %ADP-INH was not a significant predictor of any of the primary outcomes measured. H-L, Hosmer-Lemeshow. After multivariate analysis of predictors of study outcomes, the %ADP-INH, platelet count, and rTEG MA were added with the previously determined covariates to evaluate their ability to improve predictability of death, massive transfusion, or platelet transfusion. Neither %ADP-INH, platelet count, nor rTEG MA added predictive power to predict death or massive transfusion compared with the covariates alone. However, both platelet count and rTEG MA had statistically significant improvements in predicting platelet transfusion while %ADP-INH did not.
Youden index (optimal cutoff) for %ADP-INH, platelet count and MA for death, massive transfusion and platelet transfusion. The death Youden Index was 46% for %ADP-INH, 217,000/ mL for platelet count and 56 mm for MA. Regarding prediction of massive transfusion, we estimated 80% for %ADP-INH, 183,000/mL for platelet count and 56 mm for MA. For platelet transfusion, these indices were: 50% for %ADP-INH, 217,000/ mL for platelet count and 56 mm for MA.
%ADP-INH, platelet count and MA as prognostic indicators among patients who received platelet transfusion. Forty (13%) patients received platelet transfusion within 6 hours of injury. Of these, 16 was not possible to adjust using multivariate modeling due to the small sample size.
DISCUSSION
The purpose of this study was to assess whether platelet ADP receptor dysfunction, measured by TEG-PM, adds additional information in determining the need for massive transfusion, platelet transfusion or predicts mortality. This study confirmed that platelet dysfunction, as measured by %ADP-INH, occurs early after trauma and is associated with mortality, massive transfusion, or platelet transfusion. However, %ADP-INH was not a better predictor of these outcomes than platelet count, rTEG MA or even clinical indicators of injury severity and coagulation. Conversely, the prediction by platelet count and rTEG-MA added significantly to clinical indicators in the prediction of requirements of platelet transfusion.
TEG-PM was developed originally to assess antiplatelet therapy in cardiac patients taking salicylic acid or clopidogrel, 8 and recently has been suggested as a tool to evaluate platelet function in trauma patients. 3 Early studies measuring TEG-PM in trauma showed significant correlations between TBI and degree of ADP receptor inhibition with increased risk of mortality. 17, 18 In our study, the lack of significant association between %ADP-INH with TBI could be due to a type 2 error. Alternatively, it is possible that the increase in %ADP-INH may not be specific to TBI, rather it may be related to the severity of the injury. Indeed, NISS $25 is significantly associated with %ADP-INH.
The absence of increased predictive value by % ADP-INH may suggest %ADP-INH is simply a biomarker of injury severity rather than a direct mediator of TIC. Although the ADP receptor seems to have a major role in the secondary platelet response to maintain clot stability, 9 other agonists are also critical in the platelet response, including arachadonic acid, thrombin, collagen, serotonin, epinephrine, Von Willebrand factor, histone, and high mobility group box 1. 9, 10, 19 In addition, these other platelet cell surface receptors may act to compensate the dysfunction through the ADP receptor pathway, maintaining global platelet function in the injured patient and should be evaluated further in the future. For example, platelets with a high degree of ADP inhibition continue to maintain their dense granules indicating their maintained functional capacity in the injured patient and argue against the theory of platelet exhaustion as an etiology of platelet dysfunction. 12 A liberal threshold (>100,000/mL) for platelet transfusions to trauma patients has been proposed. 20 Although high ratios of platelets to RBC in retrospective trauma studies have suggested improvement in survival, randomized controlled trial data suggests that a platelet:RBC transfusion ratio higher than 1:2 does not improve survival. 6 Furthermore, the dangers of excessive platelet transfusions for intracranial bleeding were suggested in the PATCH-3 study in which empiric platelet transfusion in hemorrhagic stroke patients was associated with increased mortality. 20 Although platelet count predicts outcome, transfusing platelets based on platelet count to "normalize" platelet count does not seem to improve outcomes, and may even harm patients, if the internal environment is hostile. 21 The appropriate transfusion trigger for platelets in injured patients remains to be elucidated, but goal-directed platelet transfusions with TEG MA have been associated with a reduction in platelet transfusions and a reduction in mortality in patients undergoing massive transfusion. 7, 22, 23 There are several limitations to our study. Our work with TEG-PM has been confined to assessment of the response to ADP. In addition, these data reflect a single point in time of dynamic process and does not take into account the temporal changes of the coagulation process. Furthermore, it is possible that different injury patterns and severity induce specific platelet function responses. The present sample is not large enough to examine the effect of %ADP-INH in specific injuries. As we continue to enroll patients in our TAP database and collaborate with other investigators to produce larger, multicenter samples, we will be able to determine whether platelet dysfunction tests have a role in specific subgroups, for example more severely injured patients or patients with TBI.
In conclusion, %ADP receptor inhibition does not add predictive value for mortality, massive transfusion, or platelet transfusion in injured patients compared with platelet count or rTEG MA, thus does not seem to provide assistance in determining the need for platelet transfusion. This study illustrates the limitations of TEG-PM as a diagnostic tool to help discriminate those that are at risk for death, massive transfusion and platelet transfusion. The utility of TEG-PM as a solitary tool to guide clinical decisions continues to require refinement. The status of other platelet surface receptors may provide more useful in determining the ultimate need for platelet transfusions in injured patients.
